CD8A and graft versus host disease: Thus, we sought to measure the long-term integrity of the FRC network under conditions where GVHD had been terminated at an earlier time point using anti-CD8α antibody depletion following BMT and T cell transfer (Supplemental Figure 2D shows the effect of anti-CD8α antibody on clinical GVHD; median CD8+ T cell numbers at 4 weeks were 4.23% of live gate in control versus 0.007% in antibody-treated mice, P < 0.0001, Mann-Whitney test, 2-tailed).